Published in final edited form as:

Behav Brain Sci. 2019 January ; 42: e11. doi:10.1017/S0140525X18001036.

The value of clinical and translational neuroscience approaches to psychiatric illness

Juyoen Hur¹, Rachael M. Tillman¹, Andrew S. Fox^{4,5}, and Alexander J. Shackman^{1,2,3}

¹Department of Psychology, University of Maryland, College Park, MD 20742 USA

²Neuroscience and Cognitive Science Program, University of Maryland, College Park, MD 20742 USA

³Maryland Neuroimaging Center, University of Maryland, College Park, MD 20742 USA

⁴Department of Psychology, University of California, Davis, CA 95616 USA

⁵California National Primate Research Center, University of California, Davis, CA 95616 USA

Abstract

Borsboom and Kalis conflate biological approaches with extreme biological reductionism and common-cause models of psychopathology. In fusing these three distinct ideas, they use evidence against extreme reductionism and common causes to devalue biology. Here, we highlight recent work underscoring the value of clinical and translational neuroscience approaches for understanding the nature and origins of psychopathology and for developing improved interventions.

Keywords

affective neuroscience; biological psychiatry; clinical neuroscience; mental illness; translational neuroscience

MAIN TEXT

Borsboom & Kalis (B&K) conflate biological approaches with extreme biological reductionism and common-cause models of psychiatric illness. In fusing these three distinct ideas, B&K use evidence against extreme reductionism and common causes to devalue clinical and translational neuroscience approaches—effectively throwing the baby out with the bathwater. But, like the paper-and-pencil approaches favored by B&K, biological approaches do not necessitate either extreme reductionism or singular causes. Although mental illness is undeniably based in brains and genes (Geschwind & Flint, 2015; Turkheimer, 1998), we agree with B&K that biological interventions are not necessarily the only or even the best way of tackling every mental illness (Kendler, 2012; Lilienfeld, 2014; Miller, 2010). Likewise, we agree that psychopathology reflects the interaction of multiple

contexts and causes—from molecular pathways to culture—with their importance varying across individuals, development, sexes, and disorders (Birnbaum & Weinberger, 2017; Kendler, 2012; Shackman & Fox, *in press*).

The network framework championed by B&K describes patterns among symptoms, but it fails to provide a deeper explanation—biological, cognitive, or computational—of where those patterns come from. With respect to risk and etiology, it focuses on symptoms, environmental factors (e.g., stress), and the connection strengths (covariance) among them. Although this framework can describe variation in risk and resilience, it cannot explain why some individuals and their biological relatives are predisposed to experience specific symptoms in maladaptive ways or how environmental factors interact with particular symptoms to produce psychopathology. In contrast, biological approaches are beginning to do just that:

- Anxiety patients and individuals at risk for developing anxiety disorders show increased amygdala activity (Etkin & Wager, 2007; Fox et al., 2015; Fox & Shackman, *in press*) and aberrant amygdala connectivity (Birn et al., 2014)
- Extended amygdala activity is heritable (Fox et al., 2015), associated with specific molecular pathways (Fox et al., 2012; Roseboom et al., 2014), and amplified by stress (Shackman, Kaplan, et al., 2016)
- Heightened amygdala reactivity confers risk for the development of future internalizing symptoms, particularly among individuals exposed to stress (Shackman, Kaplan, et al., 2016)
- Anxiolytics dampen amygdala reactivity (e.g., Del-Ben et al., 2012)
- Amygdala damage markedly reduces signs and symptoms of anxiety in humans and monkeys (Feinstein, Adolphs, Damasio, & Tranel, 2011; Oler, Fox, Shackman, & Kalin, 2016)

These findings suggest that circuits encompassing the extended amygdala causally contribute to the development of maladaptive anxiety (Shackman, Tromp, et al., 2016). Such observations are hardly limited to the amygdala and anxiety. Other work highlights the importance of ventral striatal circuits to anhedonia (Bewernick, Kayser, Sturm, & Schlaepfer, 2012; Greer, Trujillo, Glover, & Knutson, 2014; Nugent et al., 2014; Pizzagalli, 2014; Schlaepfer et al., 2008; Stringaris et al., 2015).

In rejecting common-cause models, B&K neglect evidence that uncorrelated and dissimilar disease phenotypes can reflect common substrates (Kotov et al., 2017; Zhu, Need, Petrovski, & Goldstein, 2014), a pattern not readily explained by symptom-network models. Individual differences in amygdala metabolism, for example, are associated with both neuroendocrine and behavioral signs of anxiety—two phenotypes that are only weakly correlated with one another (Shackman et al., 2013). Likewise, lesions and other perturbations of the amygdala produce coherent changes in a range of disease-relevant phenotypes—neuroendocrine activity, passive avoidance, vigilance, and anxious feelings—suggesting that the amygdala-centered circuits represent a (but likely not the only) common cause for some (but not all)

key features of pathological anxiety (Fox & Shackman, *in press*; Inman et al., *in press*; Oler et al., 2016).

Mental illness imposes a staggering burden on global public health and there is an urgent need to develop better treatments (Global Burden of Disease Collaborators, 2016). Symptom-network approaches to treatment represent, at best, incremental improvements over current clinical practice. Most clinicians already focus more on symptoms and their interconnections than on DSM diagnoses and their myriad specifiers (Waszczuk et al., 2017). In contrast to symptom-network approaches, recent biological research highlights the possibility of developing completely new interventions and more efficiently matching patients to treatments ('stratified medicine;' Drysdale et al., 2017; Woo, Chang, Lindquist, & Wager, 2017). On-going genomics research represents one of the few feasible paths to identifying and prioritizing new molecular targets, a prerequisite for developing improved drugs (Gandal, Leppa, Won, Parikshak, & Geschwind, 2016; Pankevich, Altevogt, Dunlop, Gage, & Hyman, 2014). In short, biological approaches afford opportunities for improving the lives of patients that go far beyond those afforded by symptom-centric frameworks.

So where do we go from here? B&K remind us that clinical and translational neuroscience has historically been oversold and under-delivered (for a related perspective, see Gordon & Redish, 2016). Billions of dollars have, as yet, failed to uncover new assays or cures (Shackman & Fox, *in press*). Although B&K tell us that this reflects the futility of biological reductionism, a growing number of clinicians and neuroscientists—including the architects of the National Institute of Mental Health Research Domain Criteria (RDoC)—have concluded that past underperformance reflects limitations of DSM diagnoses, rather than any intrinsic limitation of biological approaches (Gordon & Redish, 2016; Kozak & Cuthbert, 2016).

Categorical diagnoses pose several critical barriers to discovering the nature and origins of psychopathology, including rampant co-morbidity, low symptom specificity, marked symptom heterogeneity, and poor reliability (Fried & Nesse, 2015; Galatzer-Levy & Bryant, 2013; Hasin et al., 2015; Kessler, Chiu, Demler, & Walters, 2005; Krueger et al., *in press*; Olbert, Gala, & Tupler, 2014; Regier et al., 2013; Watson & Stasik, 2014). Addressing these problems requires that we focus on understanding the computational, cognitive, and biological bases of circumscribed symptoms or symptom clusters (e.g., anxiety, anhedonia). This 'symptoms-not-syndromes' approach (Fried, 2015) would also more naturally align with animal models (Fox & Shackman, *in press*).

In conclusion, there is a real intellectual danger to adopting B&K's framework wholesale. Although symptom-network approaches are valuable, they steer us away from deeper explanations for why some individuals and their biological relatives are prone to particular symptoms. A more holistic approach, one that embraces both biological and non-biological approaches, is likely to yield greater dividends for understanding the nature and bases of psychopathology and accelerate the development of improved treatments.

Acknowledgments

Authors acknowledge assistance from K. DeYoung and L. Friedman. This work was supported by the California National Primate Center; University of California, Davis; University of Maryland, College Park; and National Institutes of Health (DA040717 and MH107444).

References

- Bewernick BH, Kayser S, Sturm V, Schlaepfer TE. 2012; Long-term effects of nucleus accumbens deep brain stimulation in treatment-resistant depression: evidence for sustained efficacy. *Neuropsychopharmacology*. 37:1975–1985. [PubMed: 22473055]
- Birn RM, Shackman AJ, Oler JA, Williams LE, McFarlin DR, Rogers GM, ... Kalin NH. 2014; Evolutionarily conserved dysfunction of prefrontal-amygdalar connectivity in early-life anxiety. *Molecular Psychiatry*. 19:915–922. [PubMed: 24863147]
- Birnbaum R, Weinberger DR. 2017; Genetic insights into the neurodevelopmental origins of schizophrenia. *Nature Reviews Neuroscience*. 18:727–740. [PubMed: 29070826]
- Del-Ben CM, Ferreira CA, Sanchez TA, Alves-Neto WC, Guapo VG, de Araujo DB, Graeff FG. 2012; Effects of diazepam on BOLD activation during the processing of aversive faces. *J Psychopharmacol*. 26:443–451. [PubMed: 21106607]
- Drysdale AT, Grosenick L, Downar J, Dunlop K, Mansouri F, Meng Y, ... Liston C. 2017; Resting-state connectivity biomarkers define neurophysiological subtypes of depression. *Nature Medicine*. 23:28–38.
- Etkin A, Wager TD. 2007; Functional neuroimaging of anxiety: a meta-analysis of emotional processing in PTSD, social anxiety disorder, and specific phobia. *American Journal of Psychiatry*. 164:1476–1488. [PubMed: 17898336]
- Feinstein JS, Adolphs R, Damasio A, Tranel D. 2011; The human amygdala and the induction and experience of fear. *Current Biology*. 21:1–5. [PubMed: 21129968]
- Fox AS, Oler JA, Shackman AJ, Shelton SE, Raveendran M, McKay DR, ... Kalin NH. 2015; Intergenerational neural mediators of early-life anxious temperament. *Proceedings of the National Academy of Sciences USA*. 112:9118–9122.
- Fox AS, Oler JA, Shelton SE, Nanda SA, Davidson RJ, Roseboom PH, Kalin NH. 2012; Central amygdala nucleus (Ce) gene expression linked to increased trait-like Ce metabolism and anxious temperament in young primates. *Proceedings of the National Academy of Sciences of the United States of America*. 109:18108–18113. [PubMed: 23071305]
- Fox AS, Shackman AJ. The central extended amygdala in fear and anxiety: Closing the gap between mechanistic and neuroimaging research. *Neuroscience Letters*.
- Fried EI. 2015; Problematic assumptions have slowed down depression research: why symptoms, not syndromes are the way forward. *Front Psychol*. 6:309. [PubMed: 25852621]
- Fried EI, Nesse RM. 2015; Depression is not a consistent syndrome: An investigation of unique symptom patterns in the STAR*D study. *Journal of Affective Disorders*. 172:96–102. [PubMed: 25451401]
- Galatzer-Levy IR, Bryant RA. 2013; 636,120 ways to have Posttraumatic Stress Disorder. *Perspect Psychol Sci*. 8(6):651–662. [PubMed: 26173229]
- Gandal MJ, Leppa V, Won H, Parikshak NN, Geschwind DH. 2016; The road to precision psychiatry: translating genetics into disease mechanisms. *Nature Neuroscience*. 19:1397–1407. [PubMed: 27786179]
- Geschwind DH, Flint J. 2015; Genetics and genomics of psychiatric disease. *Science*. 349:1489–1494. [PubMed: 26404826]
- Global Burden of Disease Collaborators. 2016; Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. *Lancet*. 388:1545–1602. [PubMed: 27733282]
- Gordon, JA, Redish, AD. On the cusp. Current challenges and promises in psychiatry. In: Redish, AD, Gordon, JA, editors. *Computational psychiatry: New perspectives on mental illness*. Cambridge, MA: MIT Press; 2016. 3–14.

- Greer SM, Trujillo AJ, Glover GH, Knutson B. 2014; Control of nucleus accumbens activity with neurofeedback. *Neuroimage*. 96:237–244. [PubMed: 24705203]
- Hasin DS, Shmulewitz D, Stohl M, Greenstein E, Aivadyan C, Morita K, ... Grant BF. 2015; Procedural validity of the AUDADIS-5 depression, anxiety and post-traumatic stress disorder modules: Substance abusers and others in the general population. *Drug and Alcohol Dependence*. 152:246–256. [PubMed: 25939727]
- Inman CS, Bijanki KR, Bass DI, Gross RE, Hamann S, Willie JT. Human amygdala stimulation effects on emotion physiology and emotional experience. *Neuropsychologia*.
- Kendler KS. 2012; The dappled nature of causes of psychiatric illness: replacing the organic-functional/ hardware-software dichotomy with empirically based pluralism. *Molecular Psychiatry*. 17:377–388. [PubMed: 22230881]
- Kessler RC, Chiu WT, Demler O, Walters EE. 2005; Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. *Archives of General Psychiatry*. 62:617–627. [PubMed: 15939839]
- Kotov R, Krueger RF, Watson D, Achenbach TM, Althoff RR, Bagby RM, ... Zimmerman M. 2017; The hierarchical taxonomy of psychopathology (HiTOP): A dimensional alternative to traditional nosologies. *Journal of Abnormal Psychology*. 126:454–477. [PubMed: 28333488]
- Kozak MJ, Cuthbert BN. 2016; The NIMH research domain criteria initiative: Background, issues, and pragmatics. *Psychophysiology*. 53:286–297. [PubMed: 26877115]
- Krueger RF, Kotov R, Watson D, Forbes MK, Eaton NR, Ruggero CJ, ... Zimmerman J. Progress in achieving empirical classification of psychopathology. *World Psychiatry*.
- Lilienfeld SO. 2014; The Research Domain Criteria (RDoC): an analysis of methodological and conceptual challenges. *Behaviour Research and Therapy*. 62:129–139. [PubMed: 25156396]
- Miller GA. 2010; Mistreating psychology in the decades of the brain. *Perspect Psychol Sci*. 5:716–743. [PubMed: 21949539]
- Nugent AC, Diazgranados N, Carlson PJ, Ibrahim L, Luckenbaugh DA, Brutsche N, ... Zarate CA Jr. 2014; Neural correlates of rapid antidepressant response to ketamine in bipolar disorder. *Bipolar Disorders*. 16:119–128. [PubMed: 24103187]
- Olbert CM, Gala GJ, Tupler LA. 2014; Quantifying heterogeneity attributable to polythetic diagnostic criteria: theoretical framework and empirical application. *Journal of Abnormal Psychology*. 123:452–462. [PubMed: 24886017]
- Oler, JA, Fox, AS, Shackman, AJ, Kalin, NH. The central nucleus of the amygdala is a critical substrate for individual differences in anxiety. In: Amaral, DG, Adolphs, R, editors. *Living without an amygdala*. NY: Guilford; 2016. 218–251.
- Pankevich DE, Altevogt BM, Dunlop J, Gage FH, Hyman SE. 2014; Improving and accelerating drug development for nervous system disorders. *Neuron*. 84:546–553. [PubMed: 25442933]
- Pizzagalli DA. 2014; Depression, stress, and anhedonia: toward a synthesis and integrated model. *Annu Rev Clin Psychol*. 10:393–423. [PubMed: 24471371]
- Regier DA, Narrow WE, Clarke DE, Kraemer HC, Kuramoto SJ, Kuhl EA, Kupfer DJ. 2013; DSM-5 field trials in the United States and Canada, Part II: test-retest reliability of selected categorical diagnoses. *American Journal of Psychiatry*. 170:59–70. [PubMed: 23111466]
- Roseboom PH, Nanda SA, Fox AS, Oler JA, Shackman AJ, Shelton SE, ... Kalin NH. 2014; Neuropeptide Y receptor gene expression in the primate amygdala predicts anxious temperament and brain metabolism. *Biological Psychiatry*. 76:850–857. [PubMed: 24342924]
- Schlaepfer TE, Cohen MX, Frick C, Kosel M, Brodesser D, Axmacher N, ... Sturm V. 2008; Deep brain stimulation to reward circuitry alleviates anhedonia in refractory major depression. *Neuropsychopharmacology*. 33:368–377. [PubMed: 17429407]
- Shackman AJ, Fox AS. Getting serious about variation: Lessons for clinical neuroscience. *Trends in Cognitive Sciences*.
- Shackman AJ, Fox AS, Oler JA, Shelton SE, Davidson RJ, Kalin NH. 2013; Neural mechanisms underlying heterogeneity in the presentation of anxious temperament. *Proceedings of the National Academy of Sciences of the United States of America*. 110:6145–6150. [PubMed: 23538303]
- Shackman AJ, Kaplan CM, Stockbridge MD, Tillman RM, Tromp DPM, Fox AS, Gamer M. 2016; The neurobiology of anxiety and attentional biases to threat: Implications for understanding

- anxiety disorders in adults and youth. *Journal of Experimental Psychopathology*. 7:311–342. [PubMed: 27917284]
- Shackman AJ, Tromp DPM, Stockbridge MD, Kaplan CM, Tillman RM, Fox AS. 2016; Dispositional negativity: An integrative psychological and neurobiological perspective. *Psychological Bulletin*. 142:1275–1314. [PubMed: 27732016]
- Stringaris A, Vidal-Ribas Belil P, Artiges E, Lemaitre H, Gollier-Briant F, Wolke S. ... Consortium I. 2015; The brain's response to reward anticipation and depression in adolescence: Dimensionality, specificity, and longitudinal predictions in a community-based sample. *American Journal of Psychiatry*. 172:1215–1223. [PubMed: 26085042]
- Turkheimer E. 1998; Heritability and biological explanation. *Psychological Review*. 105:782–791. [PubMed: 9830379]
- Waszczuk MA, Zimmerman M, Ruggero C, Li K, MacNamara A, Weinberg A, ... Kotov R. 2017; What do clinicians treat: Diagnoses or symptoms? The incremental validity of a symptom-based, dimensional characterization of emotional disorders in predicting medication prescription patterns. *Comprehensive Psychiatry*. 79:80–88. [PubMed: 28495012]
- Watson, D, Stasik, SM. Examining the comorbidity between depression and the anxiety disorders from the perspective of the quadripartite model. In: Richards, CS, O'Hara, MW, editors. *Oxford handbook of depression and comorbidity*. NY: Oxford University Press; 2014. 46–65.
- Woo CW, Chang LJ, Lindquist MA, Wager TD. 2017; Building better biomarkers: brain models in translational neuroimaging. *Nature Neuroscience*. 20:365–377. [PubMed: 28230847]
- Zhu X, Need AC, Petrovski S, Goldstein DB. 2014; One gene, many neuropsychiatric disorders: lessons from Mendelian diseases. *Nature Neuroscience*. 17:773–781. [PubMed: 24866043]